- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12.25 | Virax Biolabs Unveils $5 Million Private Placement | 3 | RTTNews | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally | 1 | Benzinga.com | ||
| 02.12.25 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11.25 | Virax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | 211 | PR Newswire | LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection... ► Artikel lesen | |
| 01.09.25 | Virax Biolabs Collaborating With Emory University On Clinical Studies | 1 | pulse2.com | ||
| 27.08.25 | Virax Biolabs (VRAX) Falls 18% on Lack of Leads | 1 | Insider Monkey | ||
| 26.08.25 | Virax Biolabs partners with Emory for long COVID diagnostic studies | 1 | Investing.com | ||
| 26.08.25 | Virax Biolabs startet mit Emory University Studien zur Long-COVID-Diagnostik | 1 | Investing.com Deutsch | ||
| 26.08.25 | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 223 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 26.08.25 | EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies | 2 | Benzinga.com | ||
| 30.07.25 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.07.25 | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
| 18.07.25 | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 5 | Seeking Alpha | ||
| 18.07.25 | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 18.07.25 | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 218 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 18.03.25 | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 228 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 23.01.25 | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 613 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01.25 | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 456 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,60 | +0,88 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| EVOTEC | 6,286 | -0,82 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| ASEP MEDICAL | 0,114 | -0,87 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,200 | +5,13 % | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions.
BOSTON and PLANO, Texas, Dec.... ► Artikel lesen | |
| AGIOS | 24,200 | 0,00 % | Agios Pharmaceuticals, Inc.: U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia | AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia... ► Artikel lesen | |
| GENPREX | 2,220 | +11,00 % | Genprex, Inc.: Genprex Provides Clinical Update on Diabetes Gene Therapy Program | Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies
AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex,... ► Artikel lesen | |
| PALISADE BIO | 1,990 | +4,74 % | Palisade Bio, Inc.: Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 | PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic... ► Artikel lesen | |
| GEOVAX LABS | 0,166 | -9,96 % | EQS-News: GeoVax Labs, Inc.: GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement | GeoVax, Inc. / Key word(s): Financial
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
08.01.2026 / 15:03 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| ANNOVIS BIO | 3,200 | -5,33 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,400 | +12,97 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination... ► Artikel lesen | |
| HUMACYTE | 1,165 | -0,85 % | Humacyte, Inc: Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,002 (-0,52 %) liegt der Kurs bei 0,366 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.